Osteonecrosis in Gaucher Disease in the era of multiple therapies: biomarker set for risk stratification from a tertiary referral center

  1. Mohsen Basiri
  2. Mohammad E Ghaffari
  3. Jiapeng Ruan
  4. Vagishwari Murugesan
  5. Nathaniel Kleytman
  6. Glenn Belinsky
  7. Amir Akhavan
  8. Andrew Lischuk
  9. Lilu Guo
  10. Katherine Klinger
  11. Pramod K Mistry  Is a corresponding author
  1. Yale University, United States
  2. Guilan University of Medical Sciences, Islamic Republic of Iran
  3. University of Toronto, Canada
  4. University of Massachusetts Dartmouth, United States
  5. Sanofi, United States

Abstract

Background: A salutary effect of treatments for Gaucher disease (GD) has been reduction in the incidence of avascular osteonecrosis (AVN). However, there are reports of AVN in patients receiving enzyme replacement therapy (ERT), and it is not known whether it is related to individual treatments, GBA genotypes, phenotypes, biomarkers of residual disease activity or anti-drug antibodies.

Objective: Prompted by development of AVN in several patients receiving ERT, we aimed to delineate the determinants of AVN in patients receiving ERT or eliglustat substrate reduction therapy (SRT) during 20 years in a tertiary referral center.

Methods: Longitudinal follow-ups of 155 GD patients between 2001 and 2021, were analyzed for episodes of AVN on therapy, type of therapy, GBA1 genotype, spleen status, biomarkers, and other disease indicators. We applied mixed-effects logistic model to delineate the independent correlates of AVN while receiving treatment.

Results: The patients received cumulative 1382 years of treatment. There were 16 episodes of AVN in 14 patients, with two episodes, each occurring in two patients. Heteroallelic p.Asn409Ser GD1 patients were 10 times (95% CI,1.5 - 67.2) more likely than p.Asn409Ser homozygous patients to develop osteonecrosis during treatment. History of AVN prior to treatment initiation was associated with 4.8-fold increased risk of AVN on treatment (95% CI, 1.5-15.2). The risk of AVN among patients receiving velaglucerase ERT was 4.68 times higher compared to patients receiving imiglucerase ERT (95% CI,1.67-13). No patient receiving eliglustat SRT suffered AVN. There was a significant correlation between GlcSph levels and AVN. Together, these biomarkers reliably predicted risk of AVN during therapy (ROC AUC 0.894, p<0.001).

Conclusions: There is a low, but significant risk of AVN in GD in the era of ERT/SRT. We found increased risk of AVN was related to GBA genotype, history of AVN prior to treatment initiation, residual serum GlcSph level, and the type of ERT. No patient receiving SRT developed AVN. These findings exemplify a new approach to biomarker applications in a rare inborn error of metabolism to evaluate clinical outcomes in comprehensively followed patients and will aid identification of GD patients at higher risk of AVN who will benefit from closer monitoring and treatment optimization.

Funding: LSD Training Fellowship from Sanofi to MB.

Data availability

This observational study is approved by Yale University IRB and each patient provided informed consent. The patients have not provided consent to sharing their data with other investigators. Interested academic, non-commercial researchers can contact the Senior Corresponding author, Dr Pramod Mistry at Pramod.mistry@yale.edu to discuss the request to access original data. They do not need to apply or submit a project proposal. All statistical analyses were performed with SPSS version 28 (SPSS Inc., Chicago, IL, USA). MedCalc version 20.026 was used for ROC curve analysis and graphs were plotted by GraphPad Prism version 9.3.1.We do not have consent to share individual patient data. Even de-identified data risks identification through age and GBA genotype information, thus violating HIPPA patient confidentiality. Upon request to the Senior Corresponding author, the PI, we will share processed version of datasets.

Article and author information

Author details

  1. Mohsen Basiri

    Department of Internal Medicine, Yale University, New Haven, United States
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-9592-4059
  2. Mohammad E Ghaffari

    Department of ENT, Head and Neck Surgery, Guilan University of Medical Sciences, Rasht, Islamic Republic of Iran
    Competing interests
    No competing interests declared.
  3. Jiapeng Ruan

    Department of Internal Medicine, Yale University, New Haven, United States
    Competing interests
    No competing interests declared.
  4. Vagishwari Murugesan

    Department of Rheumatology, University of Toronto, Toronto, Canada
    Competing interests
    No competing interests declared.
  5. Nathaniel Kleytman

    Department of Internal Medicine, Yale University, New Haven, United States
    Competing interests
    No competing interests declared.
  6. Glenn Belinsky

    Department of Internal Medicine, Yale University, New Haven, United States
    Competing interests
    No competing interests declared.
  7. Amir Akhavan

    Department of Computer and Information Science, University of Massachusetts Dartmouth, Dartmouth, United States
    Competing interests
    No competing interests declared.
  8. Andrew Lischuk

    Department of Radiology and Biomedical Imaging, Yale University, New Haven, United States
    Competing interests
    No competing interests declared.
  9. Lilu Guo

    Translational Sciences, Sanofi, Cambridge, United States
    Competing interests
    Lilu Guo, is an employee of Sanofi and may hold stocks..
  10. Katherine Klinger

    Translational Sciences, Sanofi, Framingham, United States
    Competing interests
    Katherine Klinger, is an employee of Sanofi and may hold stocks..
  11. Pramod K Mistry

    Department of Radiology and Biomedical Imaging, Yale University, New Haven, United States
    For correspondence
    pramod.mistry@yale.edu
    Competing interests
    Pramod K Mistry, Reviewing editor, eLifePKM receives a research grant from Sanofi and has received travel support from Sanofi..
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-3447-6421

Funding

Sanofi Genzyme (LSD Training Fellowship from Sanofi to MB)

  • Mohsen Basiri

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Human subjects: All participants were enrolled in our observational studies approved by Yale's IRB. Patients also were provided with verbal explanations and their data were collected after signing consent forms.HIC#0209021074HIC#1005006783

Copyright

© 2023, Basiri et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 1,602
    views
  • 333
    downloads
  • 6
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Mohsen Basiri
  2. Mohammad E Ghaffari
  3. Jiapeng Ruan
  4. Vagishwari Murugesan
  5. Nathaniel Kleytman
  6. Glenn Belinsky
  7. Amir Akhavan
  8. Andrew Lischuk
  9. Lilu Guo
  10. Katherine Klinger
  11. Pramod K Mistry
(2023)
Osteonecrosis in Gaucher Disease in the era of multiple therapies: biomarker set for risk stratification from a tertiary referral center
eLife 12:e87537.
https://doi.org/10.7554/eLife.87537

Share this article

https://doi.org/10.7554/eLife.87537

Further reading

    1. Medicine
    Gabriel O Heckerman, Eileen Tzng ... Adrienne Mueller
    Research Article

    Background: Several fields have described low reproducibility of scientific research and poor accessibility in research reporting practices. Although previous reports have investigated accessible reporting practices that lead to reproducible research in other fields, to date, no study has explored the extent of accessible and reproducible research practices in cardiovascular science literature.

    Methods: To study accessibility and reproducibility in cardiovascular research reporting, we screened 639 randomly selected articles published in 2019 in three top cardiovascular science publications: Circulation, the European Heart Journal, and the Journal of the American College of Cardiology (JACC). Of those 639 articles, 393 were empirical research articles. We screened each paper for accessible and reproducible research practices using a set of accessibility criteria including protocol, materials, data, and analysis script availability, as well as accessibility of the publication itself. We also quantified the consistency of open research practices within and across cardiovascular study types and journal formats.

    Results: We identified that fewer than 2% of cardiovascular research publications provide sufficient resources (materials, methods, data, and analysis scripts) to fully reproduce their studies. Of the 639 articles screened, 393 were empirical research studies for which reproducibility could be assessed using our protocol, as opposed to commentaries or reviews. After calculating an accessibility score as a measure of the extent to which an article makes its resources available, we also showed that the level of accessibility varies across study types with a score of 0.08 for Case Studies or Case Series and 0.39 for Clinical Trials (p = 5.500E-5) and across journals (0.19 through 0.34, p = 1.230E-2). We further showed that there are significant differences in which study types share which resources.

    Conclusion: Although the degree to which reproducible reporting practices are present in publications varies significantly across journals and study types, current cardiovascular science reports frequently do not provide sufficient materials, protocols, data, or analysis information to reproduce a study. In the future, having higher standards of accessibility mandated by either journals or funding bodies will help increase the reproducibility of cardiovascular research.

    Funding: Authors Gabriel Heckerman, Arely Campos-Melendez, and Chisomaga Ekwueme were supported by an NIH R25 grant from the National Heart, Lung and Blood Institute (R25HL147666). Eileen Tzng was supported by an AHA Institutional Training Award fellowship (18UFEL33960207).

    1. Cell Biology
    2. Medicine
    Pengbo Chen, Bo Li ... Xinfeng Zheng
    Research Article

    Background:

    It has been reported that loss of PCBP2 led to increased reactive oxygen species (ROS) production and accelerated cell aging. Knockdown of PCBP2 in HCT116 cells leads to significant downregulation of fibroblast growth factor 2 (FGF2). Here, we tried to elucidate the intrinsic factors and potential mechanisms of bone marrow mesenchymal stromal cells (BMSCs) aging from the interactions among PCBP2, ROS, and FGF2.

    Methods:

    Unlabeled quantitative proteomics were performed to show differentially expressed proteins in the replicative senescent human bone marrow mesenchymal stromal cells (RS-hBMSCs). ROS and FGF2 were detected in the loss-and-gain cell function experiments of PCBP2. The functional recovery experiments were performed to verify whether PCBP2 regulates cell function through ROS/FGF2-dependent ways.

    Results:

    PCBP2 expression was significantly lower in P10-hBMSCs. Knocking down the expression of PCBP2 inhibited the proliferation while accentuated the apoptosis and cell arrest of RS-hBMSCs. PCBP2 silence could increase the production of ROS. On the contrary, overexpression of PCBP2 increased the viability of both P3-hBMSCs and P10-hBMSCs significantly. Meanwhile, overexpression of PCBP2 led to significantly reduced expression of FGF2. Overexpression of FGF2 significantly offset the effect of PCBP2 overexpression in P10-hBMSCs, leading to decreased cell proliferation, increased apoptosis, and reduced G0/G1 phase ratio of the cells.

    Conclusions:

    This study initially elucidates that PCBP2 as an intrinsic aging factor regulates the replicative senescence of hBMSCs through the ROS-FGF2 signaling axis.

    Funding:

    This study was supported by the National Natural Science Foundation of China (82172474).